Suppression of mesenchymal phenotype in inflammatory breast cancer by EGFR tyrosine kinase inhibitor erlotinib: a novel approach to suppressing metastasis.
2007 ◽
Vol 112
(1)
◽
pp. 25-33
◽
2015 ◽
Vol 13
(9)
◽
pp. 1061-1064
◽
2006 ◽
Vol 102
(3)
◽
pp. 275-282
◽
2006 ◽
Vol 207
(2)
◽
pp. 420-427
◽
2019 ◽
Vol 29
(11)
◽
pp. 1282-1290
2011 ◽
Vol 10
(6)
◽
pp. 1102-1112
◽